- |||||||||| Trial completion, Trial completion date: Study of Enzyme Supplements to Treat Celiac Disease (clinicaltrials.gov) - Mar 6, 2018
P1/2, N=38, Completed, Recruiting --> Completed | Trial completion date: Jul 2018 --> Apr 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> Dec 2017
- |||||||||| dapsone / Generic mfg.
Phase classification, Trial termination, Trial primary completion date: Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis (clinicaltrials.gov) - Dec 14, 2017 P4, N=1, Terminated, N=15 --> 10 | Trial primary completion date: Mar 2017 --> Apr 2018 Phase classification: P=N/A --> P4 | Not yet recruiting --> Terminated | Trial primary completion date: Apr 2011 --> Mar 2012; poor enrollment and lack of funding
- |||||||||| Nucala (mepolizumab) / GSK
Trial completion: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - Feb 28, 2017 P2, N=32, Completed, Enrolling by invitation --> Withdrawn Active, not recruiting --> Completed
- |||||||||| Nucala (mepolizumab) / GSK
Enrollment closed: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - Feb 7, 2017 P2, N=32, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Enrollment closed, Trial primary completion date: Study of Enzyme Supplements to Treat Celiac Disease (clinicaltrials.gov) - Aug 19, 2015
P1/2, N=40, Active, not recruiting, Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2009 --> Dec 2014
- |||||||||| Enrollment change, Trial termination: Multidrug Blister Pack Study (clinicaltrials.gov) - Apr 15, 2015
P=N/A, N=11, Terminated, Initiation date: Aug 2014 --> Jun 2015 | Trial primary completion date: Feb 2015 --> Feb 2016 N=200 --> 11 | Suspended --> Terminated; Difficulties with patient recruitement
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Visual Distraction as a Means of Enhancing Child Resistance (clinicaltrials.gov) - Apr 7, 2015
P=N/A, N=229, Completed, N=200 --> 11 | Suspended --> Terminated; Difficulties with patient recruitement Recruiting --> Completed | N=500 --> 229 | Trial primary completion date: Dec 2014 --> Apr 2015
- |||||||||| Nucala (mepolizumab) / GSK
Trial primary completion date: Anti-IL-5 Therapy in Bullous Pemphigoid (BP) (clinicaltrials.gov) - Nov 14, 2014 P2, N=30, Recruiting, Recruiting --> Completed | N=16 --> 9 Trial primary completion date: Oct 2014 --> Dec 2016
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Enrollment open: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) - Nov 4, 2014 P1/2, N=4, Enrolling by invitation, Trial primary completion date: Oct 2014 --> Dec 2016 Not yet recruiting --> Enrolling by invitation
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Trial primary completion date: Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid (clinicaltrials.gov) - Sep 8, 2014 P3, N=18, Completed, Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Dec 2012 --> Dec 2013
|